FWM
AUTL

Forefront Wealth Management’s Autolus Therapeutics AUTL Stock Holding History

Forefront Wealth Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$53.5K Hold
26,870
– – 0.04% 70
2025
Q3 		$43.8K Hold
26,870
– – 0.03% 69
2025
Q2 		$61.3K Buy
+26,870
New +$44.4K 0.05% 62

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Forefront Wealth Management's AUTL Position: Q4 2025 in Review

Forefront Wealth Management held its Autolus Therapeutics (AUTL) position steady in Q4 2025 at 26,870 shares worth $53.5K. The position accounts for 0.04% of the portfolio, ranked #70.

Forefront Wealth Management first reported a position in AUTL in Q2 2025 and has held it in 3 quarters since. The position peaked at $61.3K in Q2 2025. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Forefront Wealth Management held 26,870 shares of Autolus Therapeutics worth $53.5K as of Q4 2025.
  • Forefront Wealth Management left its Autolus Therapeutics share count unchanged in Q4 2025.
  • Autolus Therapeutics made up 0.04% of Forefront Wealth Management's portfolio in Q4 2025, its #70 holding.
  • Forefront Wealth Management first reported a position in Autolus Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Forefront Wealth Management's Autolus Therapeutics position peaked at $61.3K in Q2 2025.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Forefront Wealth Management's 13F filing for Q4 2025, filed 23 Jan 2026.